AllianceBernstein
LYEL icon

AllianceBernstein’s Lyell Immunopharma LYEL Stock Holding History

AllianceBernstein’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,040
Closed -$119K – 3286
2025
Q1 		$119K Hold
11,040
– – ﹤0.01% 3040
2024
Q4 		$141K Hold
11,040
– – ﹤0.01% 3086
2024
Q3 		$305K Hold
11,040
– – ﹤0.01% 2910
2024
Q2 		$320K Buy
11,040
+2,298
+26% +$109K ﹤0.01% 2889
2024
Q1 		$390K Sell
8,742
-471
-5% -$20.2K ﹤0.01% 2693
2023
Q4 		$357K Buy
9,213
+480
+5% +$17.3K ﹤0.01% 2769
2023
Q3 		$257K Buy
8,733
+410
+5% +$19.5K ﹤0.01% 2874
2023
Q2 		$529K Hold
8,323
– – ﹤0.01% 2611
2023
Q1 		$393K Buy
8,323
+850
+11% +$45.5K ﹤0.01% 2671
2022
Q4 		$519K Hold
7,473
– – ﹤0.01% 2611
2022
Q3 		$1.1M Hold
7,473
– – ﹤0.01% 2231
2022
Q2 		$974K Hold
7,473
– – ﹤0.01% 2360
2022
Q1 		$755K Buy
+7,473
New +$905K ﹤0.01% 2518
2021
Q3 		– Sell
-5,000
Closed -$1.62M – 3321
2021
Q2 		$1.62M Buy
+5,000
New +$1.64M ﹤0.01% 2302

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AllianceBernstein's LYEL Position: Q2 2025 in Review

AllianceBernstein sold out of Lyell Immunopharma (LYEL) in Q2 2025, closing a stake of 11,040 shares — an estimated $119K sold.

AllianceBernstein first reported a position in LYEL in Q2 2021 and held it in 14 quarters. The position peaked at $1.62M in Q2 2021. 69 funds tracked by Wall St. Rank hold LYEL as of Q2 2025.

  • AllianceBernstein reported no remaining Lyell Immunopharma position as of Q2 2025 after selling out during the quarter.
  • AllianceBernstein sold 11,040 Lyell Immunopharma shares in Q2 2025, an estimated $119K.
  • AllianceBernstein first reported a position in Lyell Immunopharma in Q2 2021 and held it in 14 quarters.
  • AllianceBernstein's Lyell Immunopharma position peaked at $1.62M in Q2 2021.
  • 69 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2025.

Based on AllianceBernstein's 13F filing for Q2 2025, filed 14 Aug 2025.